

**Appendix Table 4. Observed-to-Expected Encounter Ratios during COVID-19 Pandemic**

	Full Study Period			Pre COVID-19			Early COVID-19			COVID-19		
	<i>Jan-Sep 2020</i>			<i>Jan-Feb 2020</i>			<i>Mar-Apr 2020</i>			<i>May-Sep 2020</i>		
	<i>n</i>	<i>O:E</i>	<i>95% CI</i>	<i>n</i>	<i>O:E</i>	<i>95% CI</i>	<i>n</i>	<i>O:E</i>	<i>95% CI</i>	<i>n</i>	<i>O:E</i>	<i>95% CI</i>
<b>Overall</b>	9,051,980	0.69	( 0.67 - 0.71 )	2,468,853	1.07	( 1.03 - 1.1 )	2,096,908	0.55	( 0.53 - 0.57 )	4,486,219	0.58	( 0.54 - 0.61 )
<b>Non-Respiratory Illness</b>	6,811,799	0.69	( 0.67 - 0.71 )	1,615,310	1.03	( 1.01 - 1.06 )	1,532,288	0.54	( 0.52 - 0.56 )	3,664,201	0.62	( 0.59 - 0.66 )
<b>All Respiratory Illness</b>	2,240,181	0.68	( 0.65 - 0.7 )	853,543	1.13	( 1.07 - 1.19 )	564,620	0.57	( 0.54 - 0.6 )	822,018	0.38	( 0.35 - 0.41 )
<b>Asthma</b>	233,275	0.46	( 0.44 - 0.48 )	62,703	0.94	( 0.89 - 0.99 )	62,052	0.46	( 0.42 - 0.49 )	108,520	0.24	( 0.22 - 0.27 )
<b>Bronchiolitis</b>	171,113	0.58	( 0.54 - 0.63 )	85,764	0.93	( 0.86 - 1 )	45,057	0.50	( 0.46 - 0.55 )	40,292	0.09	( 0.08 - 0.11 )
<b>Croup</b>	123,963	0.44	( 0.41 - 0.46 )	40,236	0.95	( 0.89 - 1.02 )	28,406	0.42	( 0.39 - 0.46 )	55,321	0.16	( 0.14 - 0.18 )
<b>Influenza</b>	205,264	1.53	( 1.32 - 1.74 )	154,898	1.96	( 1.68 - 2.24 )	46,479	0.75	( 0.66 - 0.83 )	3,887	0.13	( 0.05 - 0.22 )
<b>Pneumonia</b>	115,962	0.56	( 0.53 - 0.59 )	40,159	1.06	( 0.99 - 1.13 )	32,379	0.59	( 0.54 - 0.65 )	43,424	0.19	( 0.17 - 0.21 )
<b>Unspecified ILI</b>	1,257,919	0.65	( 0.61 - 0.68 )	434,886	1.01	( 0.95 - 1.07 )	319,194	0.60	( 0.56 - 0.65 )	503,839	0.42	( 0.38 - 0.46 )
<b>Other Respiratory Illness*</b>	132,685	0.88	( 0.78 - 0.98 )	34,897	1.05	( 0.99 - 1.12 )	31,053	0.65	( 0.58 - 0.71 )	66,735	0.92	( 0.74 - 1.09 )

\*Includes 2020 COVID-19 diagnoses